Please select the option that best describes you:
Would you offer Gemcitabine/Cisplatin (or other platinum-based regimens) for metastatic pancreatic cancer harboring somatic ATM mutations?
NCCN indicates only BRCA1/2 and PALB2 mutations
NCCN indicates only BRCA1/2 and PALB2 mutations